Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2995)	11/24/2013 8:08:04 PM
From: tommysdad	Read Replies (1) \| Respond to of 3202

<<Anybody remember if Sanofi got anything other than fedratinib when they gobbled TargeGen?>> Other random kinase inhibitors that were more crappy than fedra. None of the TargeGen molecules were ever that selective . . . certainly not tofa, bari, or ruxo-like.

To: scaram(o)uche who wrote (2995)	11/25/2013 5:04:06 PM
From: Biotech Jim	Respond to of 3202

I thought that Targegen also had an H3 histamine receptor antagonist that SNY pursued in the clinic as well. I could be wrong, but I thought that SAR110894 came from them. This mechanism is associated with CNS memory systems, and it failed recently in a AD Ph2 program. It could also be used for memory issues in schizophrenics and in certain aspects of ADHD. AD was a hard indication obviously. Maybe tommysdad can correct me if I am wrong? BJ